Aliases & Classifications for Cytomegalovirus Infection

Aliases & Descriptions for Cytomegalovirus Infection:

Name: Cytomegalovirus Infection 51 3 3
Cytomegalovirus Infections 41 69

Summaries for Cytomegalovirus Infection

MedlinePlus : 41 cytomegalovirus (cmv) is a virus found around the world. it is related to the viruses that cause chickenpox and infectious mononucleosis (mono). between 50 percent and 80 percent of adults in the united states have had a cmv infection by age 40. once cmv is in a person's body, it stays there for life. cmv is spread through close contact with body fluids. most people with cmv don't get sick and don't know that they've been infected. but infection with the virus can be serious in babies and people with weak immune systems. if a woman gets cmv when she is pregnant, she can pass it on to her baby. usually the babies do not have health problems. but some babies can develop lifelong disabilities. a blood test can tell whether a person has ever been infected with cmv. most people with cmv don't need treatment. if you have a weakened immune system, your doctor may prescribe antiviral medicine. good hygiene, including proper hand washing, may help prevent infections. centers for disease control and prevention

MalaCards based summary : Cytomegalovirus Infection, also known as cytomegalovirus infections, is related to hepatitis and clostridium difficile colitis, and has symptoms including fever and pruritus. An important gene associated with Cytomegalovirus Infection is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Cyclosporine and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and kidney, and related phenotypes are cardiovascular system and hematopoietic system

NINDS : 51 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system.

Related Diseases for Cytomegalovirus Infection

Diseases related to Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 504)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.8 IFNG IL10 IL6 KIR3DL1 TNF
2 clostridium difficile colitis 29.7 IFNG IL6 TNF
3 tuberculosis 29.4 IL10 IL6 TNF
4 microcephaly 29.4 ICAM1 IFNG IL10 TNF
5 anaplastic large cell lymphoma 29.3 ICAM1 IFNG TNF
6 neuropathy 29.3 CXCL8 IL6 TNF
7 autistic disorder 29.3 CXCL8 IFNG IL10 IL6 TNF
8 labyrinthitis 29.2 CXCL8 IL10 IL6 TNF
9 choroiditis 29.2 CXCL8 IL10 IL6 TNF
10 burns 29.1 CXCL8 IFNG IL10 IL6 TNF
11 neonatal jaundice 28.9 CCL5 ICAM1 IFNG IL10 IL6 TNF
12 rheumatoid arthritis 28.5 CCL5 CXCL8 ICAM1 IFNG IL10 IL2RA
13 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 12.3
14 neurological consequences of cytomegalovirus infection 11.9
15 idiopathic disseminated cytomegalovirus infection 11.9
16 congenital cytomegalovirus 11.7
17 cytomegalic inclusion disease 11.6
18 fetal cytomegalovirus syndrome 11.3
19 immunodeficiency 14 10.8
20 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
21 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 TNF
22 tungiasis 10.3 IFNG IL10 RAG1
23 tularemia 10.3 IFNG IL10 TNF
24 denys-drash syndrome 10.3 IFNG IL10 RAG1
25 rickettsialpox 10.3 IFNG IL10 TNF
26 urethral intrinsic sphincter deficiency 10.3 IFNG SELE TNF
27 rosacea 10.3 IFNG IL10 SELE
28 abnormal retinal correspondence 10.3 IFNG IL10 TNF
29 chronic thromboembolic pulmonary hypertension 10.3 IFNG IL10 SELE
30 hypotrichosis 4 10.2 ICAM1 IFNG TNF
31 venezuelan hemorrhagic fever 10.2 ICAM1 IFNG TNF
32 motor peripheral neuropathy 10.2 IFNG IL10 TNF
33 oral cavity cancer 10.2 ICAM1 IFNG TNF
34 peripheral artery disease 10.2 IL10 TNF VCAM1
35 dengue hemorrhagic fever 10.2 IFNG IL10 TNF
36 hypopyon ulcer 10.2 ICAM1 SELE VCAM1
37 macrodactyly of the foot 10.2 ICAM1 SELE VCAM1
38 lepromatous leprosy 10.2 IFNG IL10 IL6
39 dermatomycosis 10.2 ICAM1 SELE TNF
40 transient tic disorder 10.2 IL10 IL6 TNF
41 liver inflammatory pseudotumor 10.2 IFNG IL10 TNF
42 periosteal chondrosarcoma 10.2 ICAM1 SELE VCAM1
43 multiple mitochondrial dysfunctions syndrome 10.2 IFNG IL10 IL6
44 hypoparathyroidism-retardation-dysmorphism syndrome 10.2 IL10 IL6 TNF
45 phlegmonous dacryocystitis 10.2 ICAM1 SELE VCAM1
46 phlyctenulosis 10.2 IL10 IL6 TNF
47 powassan encephalitis 10.2 ICAM1 SELE TNF
48 conidiobolomycosis 10.2 CXCL8 IL10 TNF
49 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.2 IL10 IL6 TNF
50 gonococcal endophthalmia 10.2 IL10 IL6 TNF

Comorbidity relations with Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Cytomegalovirus Infection:



Diseases related to Cytomegalovirus Infection

Symptoms & Phenotypes for Cytomegalovirus Infection

UMLS symptoms related to Cytomegalovirus Infection:


fever, pruritus

MGI Mouse Phenotypes related to Cytomegalovirus Infection:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.24 GJB2 ICAM1 IFNG IL10 IL6 MTOR
2 hematopoietic system MP:0005397 10.23 CCL5 HLA-G ICAM1 IFNG IL10 IL2RA
3 cellular MP:0005384 10.22 GJB2 ICAM1 IFNG IL10 IL6 MTOR
4 growth/size/body region MP:0005378 10.22 GJB2 ICAM1 IFNG IL10 IL2RA IL6
5 immune system MP:0005387 10.22 IFNG IL10 IL2RA IL6 MTOR RAG1
6 homeostasis/metabolism MP:0005376 10.21 GJB2 HLA-G ICAM1 IFNG RAG1 SELE
7 endocrine/exocrine gland MP:0005379 10.1 IL6 MTOR RAG1 TNF ICAM1 IFNG
8 mortality/aging MP:0010768 10.06 GJB2 ICAM1 IFNG IL10 IL2RA IL6
9 digestive/alimentary MP:0005381 10.05 ICAM1 IFNG IL10 IL2RA IL6 RAG1
10 integument MP:0010771 9.97 GJB2 ICAM1 IFNG IL10 IL6 RAG1
11 neoplasm MP:0002006 9.73 ICAM1 IFNG IL10 IL6 RAG1 TNF
12 no phenotypic analysis MP:0003012 9.7 VCAM1 GJB2 IFNG IL10 KLRB1 MTOR
13 respiratory system MP:0005388 9.56 IFNG IL10 IL2RA IL6 MTOR RAG1
14 vision/eye MP:0005391 9.28 SELE TNF GJB2 ICAM1 IFNG IL10

Drugs & Therapeutics for Cytomegalovirus Infection

Drugs for Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 278)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
3
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
4
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
5
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1 113852-37-2 60613
6
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
9
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3, 179045-86-4
10
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 1 216503-57-0
11
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
12
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1 63585-09-1, 4428-95-9 3415
13
Triamcinolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 124-94-7 31307
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
15
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
16
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 175865-60-8 64147
17
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
18
Pancrelipase Approved Phase 4 53608-75-6
19
Probenecid Approved Phase 4,Phase 2,Phase 1 57-66-9 4911
20
Montelukast Approved Phase 4 158966-92-8 5281040
21
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
22
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
23
Infliximab Approved Phase 4 170277-31-3
24
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
25
Magnesium Sulfate Approved, Vet_approved Phase 4 7487-88-9 24083
26
Azathioprine Approved Phase 4 446-86-6 2265
27 tannic acid Approved, Nutraceutical Phase 4
28
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 4408-78-0 546
29 triamcinolone acetonide Phase 4,Phase 1,Phase 2
30 pancreatin Phase 4
31 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
32 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
33 Ganciclovir triphosphate Phase 4,Phase 3,Phase 2,Phase 1
34 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
35 Neuroprotective Agents Phase 4,Phase 2,Phase 1
36 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
37 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
39 Triamcinolone diacetate Phase 4,Phase 1,Phase 2
40 Triamcinolone hexacetonide Phase 4,Phase 1,Phase 2
41 Hormones Phase 4,Phase 3,Phase 2,Phase 1
42 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
46 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Immunoglobulin G Phase 4,Phase 3,Phase 1,Phase 2
48 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
49 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
50 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 416)
id Name Status NCT ID Phase
1 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4
2 Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients Unknown status NCT01927588 Phase 4
3 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4
4 Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients Unknown status NCT00364052 Phase 4
5 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Completed NCT01509404 Phase 4
6 Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients Completed NCT00730769 Phase 4
7 The Influence of Chronic CMV Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
8 Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients Completed NCT00436384 Phase 4
9 Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) Completed NCT00947141 Phase 4
10 Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4
11 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients Completed NCT02683291 Phase 4
12 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4
13 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
14 VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients Completed NCT00431353 Phase 4
15 Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients Completed NCT00373165 Phase 4
16 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4
17 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4
18 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4
19 Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Completed NCT01446445 Phase 4
20 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
21 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4
22 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir Completed NCT01651585 Phase 4
23 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients Completed NCT00299221 Phase 4
24 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4
25 Everolimus in de Novo Heart Transplant Recipients Completed NCT01017029 Phase 4
26 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis Completed NCT00000894 Phase 4
27 Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen Completed NCT00170820 Phase 4
28 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4
29 Organ Transplant Infection Prevention and Detection Project Completed NCT00177801 Phase 4
30 Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status Completed NCT00442975 Phase 4
31 Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients Completed NCT02503982 Phase 4
32 Montelukast in Bronchiolitis Obliterans Syndrome Completed NCT01211509 Phase 4
33 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Completed NCT00520494 Phase 4
34 Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients Completed NCT00895583 Phase 4
35 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Recruiting NCT02671318 Phase 4
36 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4
37 Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant Recruiting NCT02550639 Phase 4
38 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4
39 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients Recruiting NCT01552369 Phase 4
40 PTH - Preemptive Treatment for Herpesviridae Recruiting NCT02152358 Phase 4
41 Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction Recruiting NCT01935128 Phase 4
42 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Terminated NCT01037712 Phase 4
43 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4
44 Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy Unknown status NCT00966836 Phase 3
45 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3
46 A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV) Unknown status NCT01157949 Phase 3
47 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3
48 Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor Unknown status NCT00733733 Phase 3
49 Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection Completed NCT00881517 Phase 2, Phase 3
50 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3

Search NIH Clinical Center for Cytomegalovirus Infection

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Cytomegalovirus Infection

Anatomical Context for Cytomegalovirus Infection

MalaCards organs/tissues related to Cytomegalovirus Infection:

39
T Cells, Testes, Kidney, Liver, Lymph Node, Nk Cells, Brain

Publications for Cytomegalovirus Infection

Articles related to Cytomegalovirus Infection:

(show top 50) (show all 1349)
id Title Authors Year
1
CD4(+)CD28(null) T Cells are related to previous cytomegalovirus infection but not to accelerated atherosclerosis in ANCA-associated vasculitis. ( 28084533 )
2017
2
T and B Cell Markers in Dried Blood Spots of Neonates with Congenital Cytomegalovirus Infection: B Cell Numbers at Birth Are Associated with Long-Term Outcomes. ( 27903736 )
2017
3
Prediction of Congenital Cytomegalovirus Infection in High-Risk Pregnant Women. ( 27986675 )
2017
4
Infliximab as treatment of severe enteropathy in a patient with common variable immunodeficiency and cytomegalovirus infection. ( 28476306 )
2017
5
Congenital Cytomegalovirus Infection: Prognostic Value of Maternal DNAemia at Amniocentesis. ( 27986666 )
2017
6
Cytokine gene polymorphism associations with congenital cytomegalovirus infection and sensorineural hearing loss. ( 28501927 )
2017
7
Erdheim-Chester disease with unusual clinicopathological features complicated by DRESS syndrome, disseminated Cytomegalovirus infection and hemophagocytic lymphohistiocytosis. ( 28418177 )
2017
8
The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients. ( 28087884 )
2017
9
Pathogenesis of developmental anomalies of the central nervous system induced by congenital cytomegalovirus infection. ( 28074532 )
2017
10
RMND1-Related Leukoencephalopathy With Temporal Lobe Cysts and Hearing Loss-Another Mendelian Mimicker of Congenital Cytomegalovirus Infection. ( 27843092 )
2017
11
EP01.11: Congenital cytomegalovirus infection: an interesting case ofA clinical, molecular and pathologic correlations. ( 27646834 )
2016
12
Cytomegalovirus infection and treatment in allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution in an endemic area. ( 27610628 )
2016
13
Erythema multiforme syndrome associated with acute acquired cytomegalovirus infection. ( 27279865 )
2016
14
cGAS-STING Signaling Regulates Initial Innate Control of Cytomegalovirus Infection. ( 27334590 )
2016
15
Exploitation of IL-10 Signaling Pathways: The Alternate Roles of Viral and Cellular IL-10 in Rhesus Cytomegalovirus Infection. ( 27558431 )
2016
16
Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. ( 27132815 )
2016
17
Detection of CMV DNA in the perilymph of a 6-year-old boy with congenital cytomegalovirus infection. ( 27304443 )
2016
18
Clinical Predictors of Sensorineural Hearing Loss and Cognitive Outcome in Infants with Symptomatic Congenital Cytomegalovirus Infection. ( 27195603 )
2016
19
Longitudinal Kinetics of Cytomegalovirus-Specific T-Cell Immunity and Viral Replication in Infants With Congenital Cytomegalovirus Infection. ( 26908487 )
2016
20
Colonic perforation in a patient with systemic lupus erythematosus accompanied by cytomegalovirus infection: A case report. ( 27093690 )
2016
21
Venous thromboembolism associated with acute cytomegalovirus infection: epidemiology and predisposing conditions. ( 27141959 )
2016
22
Salivary glands and human congenital cytomegalovirus infection: What happens in early fetal life? ( 27420192 )
2016
23
In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. ( 27083761 )
2016
24
A Prognostic Neonatal Neuroimaging Scale for Symptomatic Congenital Cytomegalovirus Infection. ( 27344149 )
2016
25
Correlation Between White Matter Lesions and Intelligence Quotient in Patients With Congenital Cytomegalovirus Infection. ( 26778145 )
2016
26
Congenital Cytomegalovirus Infection and Permanent Hearing Loss in Rural North Indian Children. ( 28033238 )
2016
27
Tetraspanin CD151 promotes initial events in human cytomegalovirus infection. ( 27147745 )
2016
28
Vulvar Ulcers Leading to Cutaneous Perforation in an Immunocompetent Teenager: Expression of Cytomegalovirus Infection. ( 27195781 )
2016
29
Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. ( 26973071 )
2016
30
Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta. ( 27638253 )
2016
31
An unusual case of congenital cytomegalovirus infection-related retinopathy. ( 27266272 )
2016
32
Preventing Congenital Cytomegalovirus Infection: Protection to a 'T'. ( 26857178 )
2016
33
Intestinal manifestations of postnatal and congenital cytomegalovirus infection in term and preterm infants. ( 27529309 )
2016
34
Coexisting cytomegalovirus infection in immunocompetent patients with Clostridium difficile colitis. ( 26850320 )
2016
35
Audiovestibular consequences of congenital cytomegalovirus infection. ( 27067701 )
2016
36
Aberrant expression of interleukin-6 and its receptor in Fallopian tubes bearing an ectopic pregnancy with and without tubal cytomegalovirus infection. ( 28004013 )
2016
37
Newborn Screening for Congenital Cytomegalovirus Infection in Iran. ( 27518751 )
2016
38
Are female daycare workers at greater risk of cytomegalovirus infection? A secondary data analysis of CMV seroprevalence between 2010 and 2013 in Hamburg, Germany. ( 27158582 )
2016
39
Mood stabilizers inhibit cytomegalovirus infection. ( 27657833 )
2016
40
TLR9 -1486T/C and 2848C/T SNPs Are Associated with Human Cytomegalovirus Infection in Infants. ( 27105145 )
2016
41
Cytomegalovirus-infected duodenal ulcer with severe recurrent bleeding. ( 26852085 )
2016
42
Optimum treatment of congenital cytomegalovirus infection. ( 27043943 )
2016
43
A Portrait of the Human Organelle Proteome In Space and Time during Cytomegalovirus Infection. ( 27641956 )
2016
44
Update on treatment of cytomegalovirus infection in pregnancy and of the newborn with congenital cytomegalovirus. ( 27607910 )
2016
45
EP20.05: Discordant cytomegalovirus infection in a dichorionic twin pregnancy: a rare case of periconceptional infection. ( 27647174 )
2016
46
Cytomegalovirus Infection after CD34(+) Selected Hematopoietic Cell Transplant. ( 27178374 )
2016
47
Convallatoxin-induced reduction of methionine import effectively inhibits human cytomegalovirus infection and replication. ( 27654292 )
2016
48
Study of Soluble HLA-G in Congenital Human Cytomegalovirus Infection. ( 27699182 )
2016
49
The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection. ( 27637068 )
2016
50
Cytomegalovirus infection in immunosuppressed patients after kidney transplantation. ( 27547053 )
2016

Variations for Cytomegalovirus Infection

Expression for Cytomegalovirus Infection

Search GEO for disease gene expression data for Cytomegalovirus Infection.

Pathways for Cytomegalovirus Infection

Pathways related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14 CCL5 CXCL8 HLA-G ICAM1 IFNG IL10
2
Show member pathways
13.67 CCL5 CXCL8 IFNG IL10 IL2RA IL6
3
Show member pathways
13.57 CCL5 CXCL8 ICAM1 IFNG IL10 IL2RA
4
Show member pathways
13.42 CCL5 CXCL8 IL10 IL2RA IL6 MTOR
5
Show member pathways
13.31 CCL5 CXCL8 HLA-G ICAM1 IFNG IL10
6
Show member pathways
12.95 CCL5 CXCL8 IFNG IL10 IL6 TNF
7
Show member pathways
12.83 CCL5 CXCL8 HLA-G ICAM1 IFNG IL2RA
8
Show member pathways
12.77 CCL5 CXCL8 IFNG IL6 TNF
9
Show member pathways
12.76 CXCL8 HLA-G ICAM1 IFNG IL10 IL2RA
10
Show member pathways
12.65 IFNG IL10 IL2RA IL6 MTOR TNF
11 12.59 CCL5 IFNG IL10 IL2RA RAG1 TNF
12
Show member pathways
12.57 HLA-G ICAM1 IFNG KIR3DL1 TNF
13
Show member pathways
12.54 HLA-G ICAM1 IFNG VCAM1
14 12.48 HLA-G ICAM1 IL2RA IL6 TNF VCAM1
15
Show member pathways
12.45 IFNG IL10 IL6 TNF
16
Show member pathways
12.42 ICAM1 IL10 MTOR VCAM1
17
Show member pathways
12.4 CCL5 ICAM1 IFNG IL6 TNF
18
Show member pathways
12.37 CXCL8 IFNG IL6 TNF
19 12.34 HLA-G ICAM1 IFNG IL10
20
Show member pathways
12.31 CXCL8 IFNG IL6 TNF
21 12.28 IFNG IL10 IL6 TNF
22
Show member pathways
12.28 IFNG IL10 IL2RA IL6 MTOR
23
Show member pathways
12.23 CXCL8 IFNG IL6 TNF
24 12.22 CXCL8 IL10 IL6 TNF
25
Show member pathways
12.21 CXCL8 HLA-G IFNG IL10 IL6 TNF
26 12.17 HLA-G ICAM1 SELE VCAM1
27 12.17 ICAM1 IFNG SELE TNF VCAM1
28 12.15 HLA-G ICAM1 KIR3DL1 KLRB1 VCAM1
29 12.08 CXCL8 ICAM1 IFNG IL6 TNF
30 12.06 IFNG IL10 IL2RA IL6 KLRB1 TNF
31 12.03 CXCL8 ICAM1 IL10 IL6 TNF VCAM1
32
Show member pathways
12.02 IFNG IL10 IL6 TNF
33 12.01 CXCL8 IFNG IL6 MTOR
34 11.99 CCL5 ICAM1 IL6 SELE TNF VCAM1
35 11.97 CXCL8 IFNG IL10 IL6 TNF
36
Show member pathways
11.96 IL6 MTOR TNF
37 11.96 CXCL8 ICAM1 TNF VCAM1
38 11.91 IFNG IL6 MTOR
39 11.91 CXCL8 ICAM1 IL6 SELE TNF VCAM1
40 11.9 IL2RA IL6 TNF
41 11.89 CXCL8 ICAM1 IFNG IL6 SELE
42
Show member pathways
11.88 CXCL8 ICAM1 IL6
43 11.87 IFNG IL10 IL2RA KLRB1 TNF
44 11.85 CXCL8 IFNG IL6
45
Show member pathways
11.85 CXCL8 IFNG IL2RA TNF
46 11.85 IFNG IL10 IL6 TNF
47 11.84 CXCL8 IL10 IL6 TNF
48 11.84 CCL5 CXCL8 ICAM1 IFNG IL6 TNF
49 11.78 IFNG IL10 IL2RA IL6
50 11.75 CCL5 CXCL8 IL6 TNF

GO Terms for Cytomegalovirus Infection

Cellular components related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 CCL5 CXCL8 ICAM1 IFNG IL10 IL6
2 external side of plasma membrane GO:0009897 9.1 ICAM1 IFNG IL2RA IL6 TNF VCAM1

Biological processes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 CCL5 CXCL8 IL10 IL2RA IL6 SELE
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 CCL5 ICAM1 IL6 TNF
3 aging GO:0007568 9.95 GJB2 IL10 IL6 VCAM1
4 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.89 IL10 IL6 TNF
5 regulation of immune response GO:0050776 9.88 HLA-G ICAM1 IFNG KIR3DL1 KLRB1 VCAM1
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 ICAM1 IL6 MTOR
7 positive regulation of protein kinase B signaling GO:0051897 9.87 IL6 MTOR TNF
8 response to glucocorticoid GO:0051384 9.86 IL10 IL6 TNF
9 cellular response to interleukin-1 GO:0071347 9.86 CCL5 CXCL8 ICAM1 IL6
10 B cell differentiation GO:0030183 9.85 IL10 RAG1 VCAM1
11 regulation of insulin secretion GO:0050796 9.85 CCL5 IFNG TNF
12 cellular response to tumor necrosis factor GO:0071356 9.85 CCL5 CXCL8 ICAM1 IL6 VCAM1
13 response to lipopolysaccharide GO:0032496 9.85 GJB2 ICAM1 IL10 IL6 SELE VCAM1
14 neutrophil chemotaxis GO:0030593 9.84 CCL5 CXCL8 IFNG
15 humoral immune response GO:0006959 9.84 IFNG IL6 TNF
16 interferon-gamma-mediated signaling pathway GO:0060333 9.84 HLA-G ICAM1 IFNG VCAM1
17 positive regulation of cell adhesion GO:0045785 9.81 CCL5 IFNG TNF
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 CCL5 IFNG IL6
19 response to insulin GO:0032868 9.81 ICAM1 IL10 IL6 MTOR
20 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.8 ICAM1 SELE VCAM1
21 response to amino acid GO:0043200 9.8 ICAM1 IL6 MTOR
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 CCL5 IL6 MTOR TNF
23 negative regulation of T cell proliferation GO:0042130 9.79 HLA-G IL10 IL2RA
24 cellular response to dexamethasone stimulus GO:0071549 9.76 GJB2 ICAM1 IL6
25 defense response to protozoan GO:0042832 9.74 IFNG IL10 IL6
26 cellular response to hepatocyte growth factor stimulus GO:0035729 9.72 IL10 IL6
27 negative regulation of growth of symbiont in host GO:0044130 9.72 IFNG IL10 TNF
28 acute inflammatory response GO:0002526 9.71 IL6 VCAM1
29 negative regulation of immune response GO:0050777 9.71 HLA-G IL2RA
30 response to molecule of bacterial origin GO:0002237 9.71 CXCL8 IL10
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL10 TNF
32 positive regulation of protein import into nucleus, translocation GO:0033160 9.7 IFNG IL6
33 negative regulation of G-protein coupled receptor protein signaling pathway GO:0045744 9.7 CCL5 CXCL8
34 leukocyte tethering or rolling GO:0050901 9.7 SELE TNF VCAM1
35 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IFNG TNF
36 negative regulation of lipid storage GO:0010888 9.69 IL6 TNF
37 neutrophil activation GO:0042119 9.69 CCL5 CXCL8
38 endothelial cell apoptotic process GO:0072577 9.68 IL10 TNF
39 negative regulation of T cell apoptotic process GO:0070233 9.68 CCL5 RAG1
40 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IFNG IL10
41 negative regulation of cytokine secretion involved in immune response GO:0002740 9.66 IL10 TNF
42 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.65 IL6 TNF
43 cellular response to nutrient levels GO:0031669 9.65 ICAM1 IL6 MTOR
44 positive regulation of T cell proliferation GO:0042102 9.65 CCL5 IFNG IL2RA IL6 VCAM1
45 membrane to membrane docking GO:0022614 9.64 ICAM1 VCAM1
46 cellular response to lipopolysaccharide GO:0071222 9.63 CXCL8 ICAM1 IFNG IL10 IL6 TNF
47 leukocyte cell-cell adhesion GO:0007159 9.62 CCL5 ICAM1 SELE VCAM1
48 receptor biosynthetic process GO:0032800 9.61 IL10 TNF
49 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.61 ICAM1 TNF
50 neutrophil apoptotic process GO:0001781 9.6 IFNG IL6

Molecular functions related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CCL5 CXCL8 IFNG IL10 IL6 TNF

Sources for Cytomegalovirus Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....